Genentech is participating at the BIO International Convention 2023, taking place from June 5-8. We are excited to connect with you in person!
At Roche and Genentech, we are leveraging our unique company structure and culture to build deep and long-lasting collaborations with our partners to translate pioneering science into breakthroughs for patients.
We strongly believe that the key elements to a successful and lasting partnership are trust, shared values and openness. To revolutionize today’s standard of care, we are looking for best or first in class innovation in the following areas:
We are taking PHC toward a future where treatments are targeted towards individual patient needs and unique profiles. Partnering opportunities we are looking for:
Michael Scherer
Search & Evaluation Lead, Digital & Personalized Healthcare, Pharma Partnering
Email [email protected]We are leading the way to advance science in inflammatory and autoimmune diseases. Partnering opportunities we are looking for:
Jean Eric Charoin
Search & Evaluation Lead, Immunology & Infectious Diseases, Pharma Partnering
Email [email protected]We are advancing innovation to combat infectious diseases like HBV, influenza and MDR. Partnering opportunities we are looking for:
Jean Eric Charoin
Search & Evaluation Lead, Immunology & Infectious Diseases, Pharma Partnering
Email [email protected]We focus on advances for neurodegenerative, psychiatric and neurodevelopmental disorders. Partnering opportunities we are looking for:
Hannah Williams
Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering
Email [email protected]We focus on first- and best-in-class therapeutics in molecular targeted therapies and cancer immunotherapy. Partnering opportunities we are looking for:
Zineb El Fajoui
Search & Evaluation Lead Oncology, Pharma Partnering
Email [email protected]We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting-edge research. Partnering opportunities we are looking for:
Hannah Williams
Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering
Email [email protected]We are committed to developing new innovations for monogenetic rare diseases. Partnering opportunities we are looking for:
Hannah Williams
Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering
Email [email protected]We focus on therapeutic modalities and enabling technologies. Partnering opportunities we are looking for:
Mark Schiebler
Search & Evaluation Lead Research Technologies, Pharma Partnering
Email [email protected]Research & Development is the essence and lifeblood of Roche - and we have a unique way to foster innovation together with our partners in Asia and across the world. Partnering opportunities we are looking for:
Wenjia Li
Associate Director Business Development, Pharma Partnering China, Taiwan & Singapore
Email [email protected]Leveraging external innovation has always been central to our R&D strategy and, as such, supporting, encouraging and accessing early stage innovation is a critical aspect of our ability to discover and develop meaningful medicines for patients. Since some of the most cutting-edge science is happening in the UK, we are increasingly focusing on identifying and supporting great science in the UK. We are seeking partnering opportunities across all our therapeutic areas of interest, including digital and personalized healthcare and novel research technologies, in particular for the following:
During the collaboration conversations, a dedicated Alliance Manager is assigned as the single point of contact to ensure successful continuation and an enduring relationship with our new partner.
Out-licensing and divestment decisions enable us to continue our investment in innovative R&D, supporting the development of novel medicines. In addition, it supports the further development of programs that could result in treatments for patients in disease areas and indications that are no longer of strategic focus for Roche and Genentech.